Close Menu

financial guidance

GenMark placed 65 ePlex analyzers in Q3, the first full quarter after the platform's launch in the US, and it expects to exit 2017 with up to 200 placements.

The company saw total revenues of $27 million and product revenues of $16.9 million, as it had estimated in preliminary earnings report last month.

The company beat analyst estimates on the top and bottom lines, and said sales from its diagnostics business rose 13 percent year over year.

Excluding revenues from the sale of MDxHealth's colorectal cancer patents to Exact Sciences, total revenues increased approximately 3 percent for the period.

The company, which beat analyst estimates on both the top and bottom lines, said Cologuard test volume in Q3 2017 rose 136 percent year over year.

The company said the dramatic increase was driven by a one-time buy-out of patents related to colorectal cancer by Exact Sciences.

The company's biggest revenue increase this quarter came from its diagnostics and genomics group, though its other businesses also posted increases.

The company said revenues from its non-invasive heart transplant rejection test AlloMap rose about 16 percent year over year.

During an earnings call, company executives discussed plans to grow reimbursement of new tests, stabilize pricing, and save costs through a number of projects.

The company also launched a clinical genomics service, offering newborn screening and high-throughput NSG for rare inherited diseases.

Pages

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.